Takeda Pharmaceutical (NYSE:TAK) Sets New 12-Month High – Here’s What Happened

Takeda Pharmaceutical Co. (NYSE:TAK)’s share price reached a new 52-week high during mid-day trading on Thursday. The stock traded as high as $21.48 and last traded at $21.5780, with a volume of 8,201 shares. The stock had previously closed at $21.06.

Analysts Set New Price Targets

Several analysts have issued reports on TAK shares. Zacks Research upgraded Takeda Pharmaceutical from a “hold” rating to a “strong-buy” rating in a research note on Friday, October 30th. Wall Street Zen raised Takeda Pharmaceutical from a “hold” rating to a “buy” rating in a report on Saturday, July 18th. Finally, Weiss Ratings upgraded Takeda Pharmaceutical from a “hold (c)” rating to a “hold (c+)” rating in a report on Tuesday. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat, Takeda Pharmaceutical has a consensus rating of “Buy”.

Takeda Pharmaceutical Trading Down 0.8%

The company has a debt-to-equity ratio of 0.56, a current ratio of 1.15 and a quick ratio of 0.60. The company has a market capitalization of $67.35 billion, a price-to-earnings ratio of 11.93 and a beta of -0.02. The business has a fifty day moving average price of $19.12 and a 200 day moving average price of $17.67.

Insider Buying and Selling

In other news, insider Andrew Plump sold 116,191 shares of the company’s stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $18.49, for a total transaction of $2,148,371.59. Following the sale, the insider directly owned 145,465 shares in the company, valued at approximately $2,689,647.85. This represents a 44.41% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Lauren Duprey sold 34,535 shares of the company’s stock in a transaction that occurred on Monday, September 14th. The stock was sold at an average price of $18.54, for a total value of $640,278.90. Following the completion of the sale, the insider owned 191,522 shares in the company, valued at approximately $3,550,817.88. This represents a 15.28% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 683,074 shares of company stock worth $12,143,571 over the last 90 days. 0.04% of the stock is owned by company insiders.

Institutional Trading of Takeda Pharmaceutical

Institutional investors have recently bought and sold shares of the company. Renaissance Technologies LLC boosted its holdings in Takeda Pharmaceutical by 14.2% in the first quarter. Renaissance Technologies LLC now owns 2,989,100 shares of the company’s stock worth $55,358,000 after purchasing an additional 370,800 shares during the period. Quantinno Capital Management LP increased its stake in shares of Takeda Pharmaceutical by 20.6% in the 1st quarter. Quantinno Capital Management LP now owns 1,289,326 shares of the company’s stock valued at $23,878,000 after acquiring an additional 219,999 shares during the last quarter. Quadrant Capital Group LLC boosted its holdings in shares of Takeda Pharmaceutical by 67.8% during the 3rd quarter. Quadrant Capital Group LLC now owns 136,966 shares of the company’s stock worth $2,537,000 after buying an additional 55,360 shares during the period. Royal Bank of Canada increased its stake in shares of Takeda Pharmaceutical by 11.0% in the first quarter. Royal Bank of Canada now owns 614,851 shares of the company’s stock valued at $11,386,000 after buying an additional 60,725 shares during the period. Finally, Bleakley Financial Group LLC raised its holdings in Takeda Pharmaceutical by 19.0% during the first quarter. Bleakley Financial Group LLC now owns 431,602 shares of the company’s stock worth $7,993,000 after buying an additional 68,844 shares during the last quarter. 9.17% of the stock is currently owned by hedge funds and other institutional investors.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company is a Japan-based global biopharmaceutical company that researches, develops, manufactures and commercializes prescription medicines and vaccines. Founded in Osaka in 1781 as a medicine wholesaler, it has grown into an international pharmaceutical business headquartered in Tokyo.

The company focuses on gastroenterology and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Its portfolio includes treatments for conditions such as inflammatory bowel disease and hereditary angioedema, along with medicines and vaccines across its other therapeutic areas.

Takeda serves patients and healthcare providers in Japan and markets around the world.